OBJECTIVE： To prepare paeonol-HP-β-cyclodextrin （PAE-HP-β-CD） inclusion compound and to optimize its prescription technology. METHODS： PAE-HP-β-CD was prepared by freeze drying method and validated. Using inclusion rate as index， main drug-accessory ratio， inclusion time， inclusion temperature and stirring speed as factors， the preparation technology was optimized by central composite design-response surface methodology. RESULTS： Prepared PAE-HP-β-CD underwent phase transformation. The optimal inclusion technology was as follows as main drug-accessory ratio of 3.39 ∶ 1， inclusion temperature of 50 ℃， inclusion time of 3.2 h， stirring speed of 350 r/min. Relative error between measured value （87.46％） and predicted value （89.12％） of inclusion rate was 1.86％ （n＝6）. CONCLUSIONS： PAE-HP-β-CD inclusion compound is prepared successfully， and its prescription technology is stable and feasible.